Tuesday, 28 May 2024

Man admitted to Melbourne hospital with blood clots after AstraZeneca jab

A Victorian man has been hospitalised with blood clots after receiving the AstraZeneca vaccine in March.

Health sources with the knowledge of the case have confirmed a 44-year-old man has been admitted to the Box Hill Hospital in Melbourne’s eastern suburbs on Friday.

A Victorian man has been hospitalised with blood clots after receiving the AstraZeneca vaccine in March.Credit:Eddie Jim

Eastern Health, which oversees the Box Hill Hospital, declined to comment when contacted by The Age and The Sydney Morning Herald.

It is not yet known if the blood clots are connected to the man’s vaccination, which is believed to have occurred around March 22.

Deputy Chief Medical Officer Professor Michael Kidd and the Australian Health Protection Principal Committee, which met today, will provide an update on the case this afternoon.

The Therapeutic Goods Administration is expected to make a statement about the incident on Friday afternoon.

Both the Victorian Department of Health and TGA have been contacted for comment.

German health authorities in Berlin and Munich this week suspended the rollout of the AstraZeneca vaccine for those under the age of 60 after new concerns emerged over rare blood clotting. Canada also recently halted the rollout for people under age 55.

The pause on administering the vaccine follows a previous review of clotting by European and UK health authorities, which found the number of blood clotting cases reported after vaccination across the world was rare and lower than that expected in the general population.

Following earlier reports of cases of blood clots in patients who had been vaccinated, the TGA reviewed the preliminary data.

In a statement in mid-March, the regulator said those reviews found the AstraZeneca vaccine was not associated with an increase in the overall risk of blood clots.

“The TGA continues to closely monitor the safety of the AstraZeneca COVID-19 vaccine and will work with AstraZeneca to update product information as required,” the TGA said at the time.

“If we detect a safety concern, we will take rapid action to address it and promptly provide information to the public.”

More to come.

Most Viewed in National

From our partners

Source: Read Full Article

Related Posts